<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Empagliflozin is a potent, selective <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="105" ids="17234">glucose</z:chebi> co-transporter-2 inhibitor that is in development for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This series of studies was conducted to assess the in vivo pharmacological effects of single or multiple doses of empagliflozin in <z:chebi fb="3" ids="16646">Zucker</z:chebi> diabetic fatty rats </plain></SENT>
<SENT sid="2" pm="."><plain>Single doses of empagliflozin resulted in dose-dependent increases in urinary <z:chebi fb="105" ids="17234">glucose</z:chebi> excretion and reductions in blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="3" pm="."><plain>After multiple doses (5 weeks), fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels were reduced by 26 and 39% with 1 and 3 mg/kg empagliflozin, respectively, relative to vehicle </plain></SENT>
<SENT sid="4" pm="."><plain>After 5 weeks, HbA1c levels were reduced (from a baseline of 7.9%) by 0.3 and 1.1% with 1 and 3 mg/kg empagliflozin, respectively, versus an increase of 1.1% with vehicle </plain></SENT>
<SENT sid="5" pm="."><plain>Hyperinsulinaemic-euglycaemic clamp indicated improved insulin sensitivity with empagliflozin after multiple doses versus vehicle </plain></SENT>
<SENT sid="6" pm="."><plain>These findings support the development of empagliflozin for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>